Publication | Closed Access

Gemcitabine plus vinorelbine yields better survival outcome than vinorelbine alone in elderly patients with advanced non-small cell lung cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase III trial

OncologyElderly PatientsMedicinePhase Iii TrialClinical TrialsPharmacotherapyAnti-cancer AgentCancer TreatmentPharmacologySurvival OutcomeLung CancerMolecular Oncology